FR3077824B1 - Procede de preparation d'un lysat plaquettaire irradie - Google Patents
Procede de preparation d'un lysat plaquettaire irradie Download PDFInfo
- Publication number
- FR3077824B1 FR3077824B1 FR1851306A FR1851306A FR3077824B1 FR 3077824 B1 FR3077824 B1 FR 3077824B1 FR 1851306 A FR1851306 A FR 1851306A FR 1851306 A FR1851306 A FR 1851306A FR 3077824 B1 FR3077824 B1 FR 3077824B1
- Authority
- FR
- France
- Prior art keywords
- platelet lysate
- factor
- starting
- platelet
- factors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title abstract 2
- 239000006166 lysate Substances 0.000 abstract 8
- 108010039209 Blood Coagulation Factors Proteins 0.000 abstract 3
- 102000015081 Blood Coagulation Factors Human genes 0.000 abstract 3
- 239000003114 blood coagulation factor Substances 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 230000005855 radiation Effects 0.000 abstract 2
- 108010017384 Blood Proteins Proteins 0.000 abstract 1
- 102000004506 Blood Proteins Human genes 0.000 abstract 1
- 102100022641 Coagulation factor IX Human genes 0.000 abstract 1
- 102100023804 Coagulation factor VII Human genes 0.000 abstract 1
- 108010076282 Factor IX Proteins 0.000 abstract 1
- 108010023321 Factor VII Proteins 0.000 abstract 1
- 108010014173 Factor X Proteins 0.000 abstract 1
- 108010074864 Factor XI Proteins 0.000 abstract 1
- 108010049003 Fibrinogen Proteins 0.000 abstract 1
- 102000008946 Fibrinogen Human genes 0.000 abstract 1
- 108010094028 Prothrombin Proteins 0.000 abstract 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 abstract 1
- 229960004222 factor ix Drugs 0.000 abstract 1
- 229940012413 factor vii Drugs 0.000 abstract 1
- 229940012426 factor x Drugs 0.000 abstract 1
- 229940012952 fibrinogen Drugs 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0644—Platelets; Megakaryocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/19—Platelets; Megacaryocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2529/00—Culture process characterised by the use of electromagnetic stimulation
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Procédé de préparation d'un lysat plaquettaire irradié comprenant les étapes suivantes : - la fourniture d'un lysat plaquettaire afin d'obtenir un lysat plaquettaire de départ, ledit lysat plaquettaire de départ comprenant d'une part des facteurs plaquettaires incluant des facteurs de croissance et d'autre part des protéines plasmatiques incluant des facteurs de coagulation et des protéines autres que les facteurs de coagulation, - l'irradiation dudit lysat plaquettaire de départ, par un rayonnement UVC de longueur d'onde comprise entre 200 et 280 nm afin d'obtenir un lysat plaquettaire irradié par rayonnement UVC, ladite irradiation étant agencée pour conserver au moins 75% de la concentration en protéines totales dudit lysat plaquettaire de départ tout en réduisant d'au moins 20% la concentration en au moins un desdits facteurs de coagulation incluant le fibrinogène, le facteur II, le facteur VII, le facteur IX, le facteur X et le facteur XI du lysat plaquettaire de départ.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1851306A FR3077824B1 (fr) | 2018-02-15 | 2018-02-15 | Procede de preparation d'un lysat plaquettaire irradie |
| EP19705333.3A EP3752206A1 (fr) | 2018-02-15 | 2019-02-12 | Procédé de préparation d'un lysat plaquettaire irradié |
| PCT/EP2019/053471 WO2019158539A1 (fr) | 2018-02-15 | 2019-02-12 | Procédé de préparation d'un lysat plaquettaire irradié |
| US16/992,175 US20210115403A1 (en) | 2018-02-15 | 2019-02-12 | Method for preparing an irradiated platelet lysate |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1851306 | 2018-02-15 | ||
| FR1851306A FR3077824B1 (fr) | 2018-02-15 | 2018-02-15 | Procede de preparation d'un lysat plaquettaire irradie |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR3077824A1 FR3077824A1 (fr) | 2019-08-16 |
| FR3077824B1 true FR3077824B1 (fr) | 2022-01-14 |
Family
ID=62683307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR1851306A Active FR3077824B1 (fr) | 2018-02-15 | 2018-02-15 | Procede de preparation d'un lysat plaquettaire irradie |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20210115403A1 (fr) |
| EP (1) | EP3752206A1 (fr) |
| FR (1) | FR3077824B1 (fr) |
| WO (1) | WO2019158539A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI744300B (zh) * | 2016-03-23 | 2021-11-01 | 里爾中央醫學中心 | 改良性熱處理的血小板顆粒裂解液在製備用於治療神經系統疾病的組合物的用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2069479A1 (fr) | 2006-09-18 | 2009-06-17 | Medizinische Universität Graz | Lysat de plaquettes exempt de plasma destiné à être utilisé comme supplément dans des cultures cellulaires et pour la préparation de produits thérapeutiques cellulaires |
| EP1902740A1 (fr) * | 2006-09-19 | 2008-03-26 | Maco Pharma S.A. | Système de poches de sang et méthode pour la neutralisation des pathogènes dans un concentré de plaquettes à l'aide de ce système de poches de sang |
| EP3584310B1 (fr) * | 2008-09-16 | 2024-04-17 | Mayo Foundation for Medical Education and Research | Compositions à contenu plaquettaire |
| IL210162A0 (en) | 2010-12-21 | 2011-03-31 | Omrix Biopharmaceuticals | Viral inactivated platelet extract, use and preparation thereof |
| AU2012275562B2 (en) | 2011-06-27 | 2016-10-20 | Children's Healthcare Of Atlanta, Inc. | Compositions, uses, and preparation of platelet lysates |
| ITRM20110500A1 (it) * | 2011-09-23 | 2013-03-24 | Futura Stem Cells Sa | Lisato piastrinico, usi di esso e metodo per la sua preparazione |
| EP2733200A1 (fr) * | 2012-11-15 | 2014-05-21 | Biorigen International SA | Suppléments de culture cellulaire |
| FR3036707B1 (fr) * | 2015-05-29 | 2019-05-17 | Maco Pharma | Procede de sterilisation d'un lysat plaquettaire |
| TWI744300B (zh) | 2016-03-23 | 2021-11-01 | 里爾中央醫學中心 | 改良性熱處理的血小板顆粒裂解液在製備用於治療神經系統疾病的組合物的用途 |
-
2018
- 2018-02-15 FR FR1851306A patent/FR3077824B1/fr active Active
-
2019
- 2019-02-12 WO PCT/EP2019/053471 patent/WO2019158539A1/fr unknown
- 2019-02-12 US US16/992,175 patent/US20210115403A1/en not_active Abandoned
- 2019-02-12 EP EP19705333.3A patent/EP3752206A1/fr active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| FR3077824A1 (fr) | 2019-08-16 |
| EP3752206A1 (fr) | 2020-12-23 |
| WO2019158539A1 (fr) | 2019-08-22 |
| US20210115403A1 (en) | 2021-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111770789B (zh) | 用于处理生物流体的系统和方法 | |
| Lin et al. | Uniform nanosecond pulsed dielectric barrier discharge plasma enhances anti‐tumor effects by induction of immunogenic cell death in tumors and stimulation of macrophages | |
| Chawla et al. | UV light application as a mean for disinfection applied in the dairy industry | |
| CA2108172C (fr) | Traitement d'un materiau | |
| FR3036707B1 (fr) | Procede de sterilisation d'un lysat plaquettaire | |
| BR112017014551A2 (pt) | ?anticorpo, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos para tratamento de uma doença, para produção de um anticorpo biespecífico e para detecção da possível ocorrência de reticulação entre células com expressão de cd3 e cd20 em uma amostra derivada de um paciente, uso de um anticorpo biespecífico, e, kit? | |
| Sheth et al. | Evaluation of new technique of sterilization using biological indicator | |
| JP6840722B2 (ja) | フロースルー方式による病原体の低減 | |
| CN101738254A (zh) | 在生物液体中灭活微生物的方法 | |
| FR3077824B1 (fr) | Procede de preparation d'un lysat plaquettaire irradie | |
| Kimizuka et al. | Brief exposure of skin to near-infrared laser modulates mast cell function and augments the immune response | |
| BR0011430A (pt) | Estocagem e manutenção aperfeiçoadas de produtos de sangue incluindo células vermelhas de sangue e plaquetas | |
| PE20081841A1 (es) | Composiciones farmaceuticas con capacidad de induccion de apotosis en celulas tumorales, utiles para el diagnostico y tratamiento de la leucemia linfocitica cronica b | |
| Nyman et al. | Proteomics to study macrophage response to viral infection | |
| FR3077823B1 (fr) | Procede de preparation d'un lysat plaquettaire irradie | |
| JP2013517093A5 (fr) | ||
| Sawada et al. | Antiseptic solutions modulate the paracrine‐like activity of bone chips: differential impact of chlorhexidine and sodium hypochlorite | |
| Del Fante et al. | Comparison of two automated mononuclear cell collection systems in patients undergoing extracorporeal photopheresis: a prospective crossover equivalence study | |
| Hayashi et al. | UV light-emitting diode (UV-LED) at 265 nm as a potential light source for disinfecting human platelet concentrates | |
| BR112022005734A2 (pt) | Fotobiorreator para pasteurização de produtos alimentícios | |
| ES2343777B1 (es) | Procedimiento de recogida y envasado farmaceutico de agua de mar. | |
| WO2016069469A3 (fr) | Séparateurs pour tubes de collecte de sang | |
| Werz et al. | Strategies to avoid virus transmissions by biopharmaceutic products | |
| Mulder et al. | Corrigendum to “Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study”[Thromb. Res. vol. 185, January 2020, pages 13–19](Thrombosis Research (2020) 185 (13–19),(S0049384819304931),(10.1016/j. thromres. 2019.11. 007)) | |
| Shaker et al. | Effect of laser on erythrocytes sedimentation rate and some hematological parameters |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PLFP | Fee payment |
Year of fee payment: 2 |
|
| PLSC | Publication of the preliminary search report |
Effective date: 20190816 |
|
| PLFP | Fee payment |
Year of fee payment: 3 |
|
| PLFP | Fee payment |
Year of fee payment: 4 |
|
| PLFP | Fee payment |
Year of fee payment: 5 |
|
| PLFP | Fee payment |
Year of fee payment: 6 |
|
| PLFP | Fee payment |
Year of fee payment: 7 |